公开(公告)号：US20210213009A1

公开(公告)日：2021-07-15

申请号：US17121305

申请日：2020-12-14

Applicant: Xenon Pharmaceuticals Inc.

Inventor： James Philip JOHNSON, JR. ,  Gregory N. BEATCH

IPC: A61K31/472 ,  A61K9/00 ,  A61P23/00

Abstract: In certain embodiments, the present disclosure is directed to methods for treating pain in a subject, such as a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the subject in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US20220288057A1

公开(公告)日：2022-09-15

申请号：US17668316

申请日：2022-02-09

Applicant: XENON PHARMACEUTICALS INC.

Inventor： James Philip JOHNSON, JR.

IPC: A61K31/472 ,  A61K31/19 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/165 ,  A61K31/41 ,  A61P25/08

Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human in need thereof, wherein the methods and uses comprise conjointly administering N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) and an antiseizure medication (ASM) to the human in amounts that are therapeutically effective when conjointly administered. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.